IMPLEMENTING THE GENERALIZED RISK-ADJUSTED COST-EFFECTIVENESS (GRACE) MODEL FOR SICKLE-CELL DISEASE: A CASE STUDY

被引：0
|
作者：
Kleintjens, J. [1 ]
Mulligan, K. [2 ]
Hassan, T. [3 ]
Land, N. [3 ]
May, S. G. [3 ]
Graf, M. [3 ]
机构：
[1] PRECISIONheor, London, England
[2] Univ Southern Calif, Los Angeles, CA USA
[3] PRECISIONheor, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
EE466
引用
收藏
页码：S142 / S142
页数：1
相关论文
共 50 条
  • [21] Screening for sickle cell and thalassaemia in primary care: a cost-effectiveness study
    Bryan, Stirling
    Dormandy, Elizabeth
    Roberts, Tracy
    Ades, Anthony
    Barton, Pelham
    Juarez-Garcia, Ariadna
    Andronis, Lazaros
    Karnon, Jonathan
    Marteau, Theresa M.
    BRITISH JOURNAL OF GENERAL PRACTICE, 2011, 61 (591): : e620 - e627
  • [22] Estimated Incidence of Sickle-Cell Disease in Aruba and St Maarten suggests Cost-effectiveness of a Universal Screening Programme for St Maarten
    van Heyningen, A. M.
    Levenston, M. J.
    Tamminga, N.
    Scoop-Martijn, E. G.
    Wever, R. M. F.
    Verhagen, A. A. E.
    van der Dijs, F. P. L.
    Dijck-Brouwer, D. A. J.
    Offringa, P. J.
    Muskiet, F. A. J.
    WEST INDIAN MEDICAL JOURNAL, 2009, 58 (04): : 301 - 304
  • [23] The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
    Jiao, Boshen
    Basu, Anirban
    Roth, Joshua
    Bender, M.
    Rovira, Ilsa
    Clemons, Traci
    Quach, Dalyna
    Ramsey, Scott
    Devine, Beth
    PHARMACOECONOMICS, 2021, 39 (11) : 1225 - 1241
  • [24] Cost-effectiveness of newborn screening for sickle cell disease: a systematic review protocol
    Mahapatra, Biswajit
    Mukherjee, Nirmalya
    Khatoon, Sajda
    Bhattacharya, Paramita
    Thubru, Edakashwa
    John, Denny
    JBI EVIDENCE SYNTHESIS, 2024, 22 (06) : 1143 - 1150
  • [25] The Use of Cost-Effectiveness Analysis in Sickle Cell Disease: A Critical Review of the Literature
    Boshen Jiao
    Anirban Basu
    Joshua Roth
    M. Bender
    Ilsa Rovira
    Traci Clemons
    Dalyna Quach
    Scott Ramsey
    Beth Devine
    PharmacoEconomics, 2021, 39 : 1225 - 1241
  • [26] Reply to: Using Appropriate Methods in Cost-Effectiveness Analyses: The Case of Allogeneic Hematopoietic Cell Transplantation in Sickle Cell Disease
    Arnold, Staci D.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2016, 22 (11) : 2110 - 2111
  • [27] JAUNDICE IN NEONATES WITH SICKLE-CELL DISEASE - A CASE-CONTROL STUDY
    BAINBRIDGE, R
    KHOURY, J
    MIMOUNI, F
    AMERICAN JOURNAL OF DISEASES OF CHILDREN, 1988, 142 (05): : 569 - 572
  • [28] A TRANSGENIC MOUSE MODEL OF SICKLE-CELL DISEASE FOR STUDY OF CHRONIC VASOOCCLUSION
    MANCI, EA
    COOKE, CB
    CULBERSON, DE
    COSTANTINI, F
    FABRY, ME
    LABORATORY INVESTIGATION, 1994, 70 (01) : A134 - A134
  • [29] Universal versus targeted screening of infants for sickle cell disease: A cost-effectiveness analysis
    Panepinto, JA
    Magid, D
    Rewers, MJ
    Lane, PA
    JOURNAL OF PEDIATRICS, 2000, 136 (02): : 201 - 208
  • [30] A COMPARISON OF GENERALIZED RISK ADJUSTED COST-EFFECTIVENESS ANALYSIS (GRACE) VS TRADITIONAL COST-EFFECTIVE ANALYSIS (CEA) ESTIMATES FOR THE TREATMENT OF EARLY-ONSET METACHROMATIC LEUKODYSTROPHY (MLD)
    Ortega, L.
    Incerti, D.
    Bean, K.
    Fields, C.
    Pang, F.
    Lakdawalla, D.
    VALUE IN HEALTH, 2024, 27 (12) : S73 - S73
12345